What exactly is a “glipizide synthesis” patent about?
The phrase “glipizide synthesis patent cyclohexyl isocyanate sulfonamide” points to patent literature that uses, or is built around, a specific chemical building block: cyclohexyl isocyanate reacted with a sulfonamide-containing intermediate to form a key transformation in a glipizide (or glipizide-related) synthesis route. Patents commonly claim:
- particular reactants and conditions,
- specific intermediate structures,
- and the steps that convert those intermediates into glipizide.
With only the wording you provided, I can’t identify which specific patent document you mean (there are many glipizide process patents and multiple sulfonamide/isocyanate variants in chemical manufacturing literature).
Which patents mention cyclohexyl isocyanate and sulfonamide for glipizide?
To find the exact patent, you typically need at least one of the following:
- a patent number (US/EP/WO),
- an assignee/company name,
- an approximate filing year,
- an excerpt of the claim (verbatim wording helps a lot),
- or the full chemical name of the sulfonamide intermediate used in the document.
If you share any of those details, I can narrow to the exact document and summarize what it claims and where cyclohexyl isocyanate and the sulfonamide enter the synthesis.
How does cyclohexyl isocyanate fit into glipizide synthesis (chemistry-wise)?
In general patent chemistry terms, cyclohexyl isocyanate is an isocyanate reagent used to introduce a urea/urethane-like functionality or to drive formation of an N-containing linkage from an amine/sulfonamide precursor. In many medicinal-process patents, “isocyanate + sulfonamide/amine” is used to:
- form an amide/urea-type bond,
- generate a protected or activated intermediate,
- and then cyclize or further transform into the glipizide scaffold depending on the rest of the intermediates in the route.
However, the exact role (which bond is formed, and at what stage) depends entirely on the specific intermediate structures claimed in the patent.
What sulfonamide structure is being used?
“Sulfonamide” is a class, not a single molecule. Glipizide manufacturing routes (and glipizide-derivative chemistry) can involve different sulfonamide substitution patterns, such as aryl sulfonamides with varying ring substitutions. The exact position of substituents affects:
- reactivity with the isocyanate,
- purification needs,
- and yields/impurities.
To interpret the patent correctly, you need the specific sulfonamide name or structure referenced in the claims/examples.
Is this a valid patent claim or part of examples (not necessarily the core claim)?
In patents, the reagent can appear in:
- the independent claims (core protected method),
- or only in dependent claims and examples (which may or may not define the legally protected scope).
This matters for “is it protected” questions: if cyclohexyl isocyanate appears only in examples, a process that uses a different isocyanate might still avoid the exact claim language unless doctrine-of-equivalents issues apply.
If you’re trying to assess infringement or freedom-to-operate, what matters?
To evaluate whether a glipizide synthesis using cyclohexyl isocyanate/sulfonamide could land in a patent’s scope, you’d check:
- claim language (independent claims first),
- whether cyclohexyl isocyanate is explicitly required or just one of many “suitable isocyanates,”
- whether the sulfonamide is specifically defined (exact structure vs “a sulfonamide”),
- step sequence and conditions (temperature, solvent, time),
- and jurisdiction-specific claim construction.
If you tell me the patent number and jurisdiction (e.g., US vs EP/WO), I can help map these elements to the chemistry you’re interested in.
What you can do next (so I can identify the exact patent)
Send any one of these and I’ll produce a precise patent summary:
- the patent number (e.g., “WO…”, “US…”, “EP…”),
- the assignee/company name,
- a quoted sentence from the claim mentioning “cyclohexyl isocyanate” and “sulfonamide,”
- or the full reagent/intermediate names from the example section.
Sources: none provided (no patent text or links were included in your message).